EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Engineering the Universal Donor: CRISPR-Mediated Blood Group Antigen Deletion and the Path Toward Truly Universal Red Blood Cells—A Narrative Review

Malik A Altayar iD

Diagnostics · 03.08.2026 · 16 (15) · 2448

DOI: 10.3390/diagnostics16152448 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Diagnostics, online erschienen am 03.08.2026. Verfasst von Malik A Altayar. Beteiligte Einrichtung: Department of Medical Laboratory Technology, Faculty of Applied Medical Sciences, University of Tabuk, Tabuk 71491, Saudi Arabia. Die Arbeit nennt 71 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The designation of O RhD-negative blood as a “universal donor” misrepresents the complexity of red blood cell (RBC) compatibility. With 47 recognized blood group systems encompassing 366 antigens, non-ABO antigen exposure drives alloimmunization in 20–50% of chronically transfused patients. A narrative review of PubMed, Scopus, and EMBASE was conducted for studies published between 2016 and 2025, with selective inclusion of foundational pre-2016 works. Enzymatic approaches using Flavonifractor plautii CAZymes and Akkermansia muciniphila exoglycosidase cocktails enable near-complete ABO antigen removal, though group A conversion remains incomplete. CRISPR-Cas9 multiplex editing of immortalized erythroblasts has achieved simultaneous deletion of ABO, Rh, Kell, Duffy, and MNS antigens. Induced pluripotent stem cell platforms enable scalable manufacture; however, enucleation efficiency (40–70%), yield (4.6 × 103 RBCs/iPSC), and fetal hemoglobin prevalence remain translational barriers. Convergence of enzymatic and gene-editing technologies on GMP-compatible iPSC platforms represents the most credible pathway to truly universal RBCs, although current evidence remains largely confined to immortalized cell lines and early-stage iPSC proof-of-concept studies rather than clinically validated products. Regulatory frameworks, scalability, and rigorous off-target profiling define the key challenges ahead.

Schlagwörter

Stichwörter der Autor:innen

CRISPR-Cas9alloimmunizationblood group antigensenzymatic conversioniPSC-derived red cellsred blood cell engineeringtransfusion medicineuniversal donor blood

Autor:innen und Institutionen

  • Department of Medical Laboratory Technology, Faculty of Applied Medical Sciences, University of Tabuk, Tabuk 71491, Saudi Arabia.

ORCID-Profile: Malik A Altayar

Zitieren

APA

Altayar, M. A. (2026). Engineering the Universal Donor: CRISPR-Mediated Blood Group Antigen Deletion and the Path Toward Truly Universal Red Blood Cells—A Narrative Review. Diagnostics, 16(15), 2448. https://doi.org/10.3390/diagnostics16152448

Vancouver

Altayar MA. Engineering the Universal Donor: CRISPR-Mediated Blood Group Antigen Deletion and the Path Toward Truly Universal Red Blood Cells—A Narrative Review. Diagnostics. 2026;16(15):2448. doi:10.3390/diagnostics16152448

BibTeX
@article{Altayar2026,
  author = {Altayar, Malik A},
  title = {Engineering the Universal Donor: CRISPR-Mediated Blood Group Antigen Deletion and the Path Toward Truly Universal Red Blood Cells—A Narrative Review},
  journal = {Diagnostics},
  year = {2026},
  volume = {16},
  number = {15},
  pages = {2448},
  doi = {10.3390/diagnostics16152448}
}
Kostenlos starten →